Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations
Cancer Letters · 2025-06 · 619 · 217668
DOI: 10.1016/j.canlet.2025.217668 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-06. Verfasst von Yasuaki Uemoto und 12 weiteren Autor:innen. Beteiligte Einrichtung: UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Receptor, Fibroblast Growth Factor, Type 1, Receptor, Fibroblast Growth Factor, Type 2, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, U.S. Department of Defense, NCI.
Abstract (Originalsprache)
FGFR1 amplification and FGFR1/2 activating mutations have been associated with antiestrogen resistance in estrogen receptor-positive (ER+) breast cancer. However, there are no approved FGFR1-targeted therapies for breast cancers harboring these alterations. In this study, we investigated the selective degradation of FGFR1/2 using the proteolysis-targeting chimera (PROTAC) DGY-09-192 as a novel therapeutic strategy in ER + breast cancers harboring FGFR1/2 somatic alterations. Treatment of ER+/FGFR1-amplified breast cancer cells and patient-derived xenografts with DGY-09-192 resulted in sustained degradation of FGFR1 in a proteasome-dependent manner and suppressed downstream signal transduction. The combination of DGY-09-192 and the ERα degrader fulvestrant resulted in complete cell growth arrest and tumor regression of ER+/FGFR1-amplified patients-derived xenografts. In addition, we tested the effect of DGY-09-192 on breast cancer cells expressing FGFR1N546K and FGFR2K659E hotspot kinase domain mutations as well as ER-negative breast cancer cells harboring FGFR2 gene amplification. Treatment with DGY-09-192 resulted in the degradation of mutant FGFR1/2 and blocked mutant receptor-induced signal transduction and antiestrogen resistance. Collectively, our study suggests that degradation of FGFR1/2, in combination with antiestrogens, can be leveraged as a therapeutic strategy in ER + breast cancers harboring FGFR1/2 driver alterations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USA.
- Department of Biochemistry, UT Southwestern Medical Center, Dallas, TX, USA.
- UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USA; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.
- UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USA. Electronic address: Hanker@UTSouthwestern.edu.
- UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USA. Electronic address: Carlos.Arteaga@UTSouthwestern.edu.
Förderung
- NCI NIH HHS
- U.S. Department of Defense
- NCI
Zitieren
APA
Uemoto, Y., Lin, C. A., Wang, B., Ye, D., Fang, Y. V., Bikorimana, E., Napolitano, F., Chica-Parrado, M. R., Li, C., Mendiratta, S., Chen, C., Hanker, A. B., & Arteaga, C. L. (2025). Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations. Cancer Letters, 619, 217668. https://doi.org/10.1016/j.canlet.2025.217668
Vancouver
Uemoto Y, Lin CA, Wang B, Ye D, Fang YV, Bikorimana E, et al. Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations. Cancer Letters. 2025;619:217668. doi:10.1016/j.canlet.2025.217668
BibTeX
@article{Uemoto2025,
author = {Uemoto, Yasuaki and Lin, Chang-Ching A and Wang, Bingnan and Ye, Dan and Fang, Yisheng V and Bikorimana, Emmanuel and Napolitano, Fabiana and Chica-Parrado, Maria Rosario and Li, Cheung and Mendiratta, Saurabh and Chen, Chuo and Hanker, Ariella B and Arteaga, Carlos L},
title = {Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations},
journal = {Cancer Letters},
year = {2025},
volume = {619},
pages = {217668},
doi = {10.1016/j.canlet.2025.217668}
}
EUVIMED